XT
VTGN icon

XTX Topco’s VistaGen Therapeutics VTGN Stock Holding History

XTX Topco’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87.4K Buy
+152,849
New +$92.9K ﹤0.01% 3146
2025
Q4 		– Sell
-69,712
Closed -$247K – 3861
2025
Q3 		$247K Buy
+69,712
New +$208K 0.01% 1665
2022
Q3 		– Sell
-2,294
Closed -$61K – 1412
2022
Q2 		$61K Sell
2,294
-758
-25% -$26.8K 0.02% 727
2022
Q1 		$114K Buy
+3,052
New +$133K 0.05% 496

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XTX Topco's VTGN Position: Q1 2026 in Review

XTX Topco opened a new position in VistaGen Therapeutics (VTGN) in Q1 2026: 152,849 shares worth $87.4K. The stake represents ﹤0.01% of the portfolio and ranks #3146 among its holdings. This is a return to the name: XTX Topco previously reported a position in VTGN as recently as Q3 2025.

XTX Topco first reported a position in VTGN in Q1 2022 and has held it in 4 quarters since. The position peaked at $247K in Q3 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • XTX Topco held 152,849 shares of VistaGen Therapeutics worth $87.4K as of Q1 2026.
  • VistaGen Therapeutics was a new XTX Topco position in Q1 2026.
  • VistaGen Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3146 holding.
  • XTX Topco first reported a position in VistaGen Therapeutics in Q1 2022 and has held it in 4 quarters since.
  • XTX Topco's VistaGen Therapeutics position peaked at $247K in Q3 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.